Bluejay Therapeutics: Funding, Investors & Team (Sep 2026)
Bluejay Therapeutics is a private biopharmaceutical company that is working on developing treatments for infectious diseases. Their primary focus is on finding a cure for chronic Hepatitis B, which is a prevalent disease globally and has a critical need for medical solutions. Bluejay is progressing with two unique methods that offer a high chance of achieving a functional cure: top-grade human IgG1 anti-HBs monoclonal antibodies and novel HBsAg oral small molecule inhibitors. The company is hopeful that by diminishing hepatitis B surface antigen levels and reinstating adaptive immunity, patients can achieve a functional cure.
Bluejay Therapeutics has raised $182M across 1 funding round on record, the most recent a Series C of $182M announced in May 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Bluejay Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2024.
Bluejay Therapeutics Funding Rounds
Bluejay Therapeutics Founders and Leadership Team
Contact details for the Bluejay Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Bluejay Therapeutics Funding Compared to Other Biotechnology Startups
Bluejay Therapeutics' latest round of $182M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Bluejay Therapeutics in Biotechnology and San Francisco
Companies Similar to Bluejay Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Bluejay Therapeutics Funding FAQs
What does Bluejay Therapeutics do?
Bluejay Therapeutics is a private biopharmaceutical company that is working on developing treatments for infectious diseases. Their primary focus is on finding a cure for chronic Hepatitis B, which is a prevalent disease globally and has a critical need for medical solutions. Bluejay is progressing with two unique methods that offer a high chance of achieving a functional cure: top-grade human IgG1 anti-HBs monoclonal antibodies and novel HBsAg oral small molecule inhibitors. The company is hopeful that by diminishing hepatitis B surface antigen levels and reinstating adaptive immunity, patients can achieve a functional cure.
How much funding has Bluejay Therapeutics raised?
Bluejay Therapeutics has raised $182M across 1 round on record. The most recent is a Series C of $182M announced in May 2024.
When did Bluejay Therapeutics last raise funding?
Bluejay Therapeutics' most recent funding round on record is a Series C of $182M, announced in May 2024.
Who founded Bluejay Therapeutics?
FundedIQ lists Keting Chu (Founder) at Bluejay Therapeutics.
Where is Bluejay Therapeutics headquartered?
Bluejay Therapeutics is based in San Francisco, California, United States.
How many employees does Bluejay Therapeutics have?
Bluejay Therapeutics is in the 11-50 employee band.
How does Bluejay Therapeutics' funding compare to other Biotechnology startups?
Bluejay Therapeutics' latest round of $182M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Bluejay Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bluejay Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.